SCHEMBL24802129

SCHEMBL24802129

CN1CCC(N2CCN(C(=O)CN3CCN(C)CC3)CC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 2/20 0.49
L3MBTL3 Q96JM7 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GAA P10253 2/20 0.46
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ACHE P22303 2/20 0.45
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
F10 P00742 2/20 0.43
PKM P14618 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
MAPT P10636 1/20 0.40
CACNA2D1 P54289 1/20 0.39
CACNA1B Q00975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766167 0.92 SIGMAR1 (0.50) ALDH1A1KDM4EL3MBTL3L3MBTL1GAA
SCHEMBL24204406 0.91 ALDH1A1 (0.45) ALDH1A1KDM4EL3MBTL3L3MBTL1GAA
SCHEMBL24352086 0.91 ALDH1A1 (0.45) ALDH1A1KDM4EL3MBTL3L3MBTL1GAA
SCHEMBL21281275 0.88 KDM4E (0.65) ALDH1A1KDM4EL3MBTL3L3MBTL1GAA
SCHEMBL24204316 0.86 L3MBTL3 (0.47) ALDH1A1L3MBTL3L3MBTL1ACHETSHR
SCHEMBL11952846 0.84 GAA (0.61) ALDH1A1GAALMNARECQLSMN1; SMN2
SCHEMBL3767809 0.83 SIGMAR1 (0.57) ALDH1A1KDM4EGAALMNARECQL
SCHEMBL27456322 0.83 KDM4E (0.46) ALDH1A1KDM4EL3MBTL3L3MBTL1GAA
SCHEMBL3448427 0.83 ALDH1A1 (0.43) ALDH1A1KDM4EL3MBTL3L3MBTL1GAA
SCHEMBL3450967 0.83 ALDH1A1 (0.43) ALDH1A1KDM4EL3MBTL3L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 US disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 US disclosed
WO-2022268052-A9 (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE BEIGENE, LTD. (KY) 2023-08-17 WO disclosed
WO-2022268052-A1 (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE BEIGENE, LTD. (KY) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 ALDH1A1 3281/4885KDM4E 1783/4885L3MBTL3 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.